Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Next Previous
X
Search
Trial Profile

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Prednisone; Vincristine
  • Indications B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms Inter-B-NHL ritux 2010

    • Most Recent Events

    • 10 Jul 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 16 Feb 2024 This study has been completed in Poland, according to European Clinical Trials Database record.
    • 23 Oct 2023 This study has been completed in Netherland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top